
Conference Coverage
Latest Content

Sonrotoclax Receives FDA Priority Review for R/R Mantle Cell Lymphoma

Colorectal Cancer Screening In Younger Adults Increases After Guideline Changes

Health Outcomes of Dually Eligible Beneficiaries Under Different Medicare Payment Arrangements

From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care

Study Challenges Link Between Social Media Use and Body Image

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.

Medicare Advantage beneficiaries with mental health diagnoses see more nurse practitioners and fewer internal medicine and emergency medicine specialists after switching to traditional Medicare.

Global chronic lymphocytic leukemia incidence and mortality is declining, but the disease’s prevalence has increased modestly.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Elevated levels of a combined biomarker integrating CRP, triglycerides, and glucose are associated with increased risk of rheumatoid arthritis.

In real-world usage, 97% of cases of cytokine release syndrome following treatment with lisocabtagene maraleucel happened within 15 days of infusion.

Ryan Haumschild, PharmD, discusses overcoming barriers to cancer care access, emphasizing the role of pharmacy in improving access and affordability.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

ATTRibute-CM data show acoramidis reduced mortality in ATTRwt-CM and ATTRv-CM and raised serum transthyretin through 42 months.

Over 50% of patients with high-grade serous ovarian cancer (HGSOC) had surgery, often decades before diagnosis, where salpingectomy could have reduced risk.


























































